mRNA-derived Prostate Cancer Vaccine CV9104

Known as: CV9104, RNActive-derived Prostate Cancer Vaccine CV9104 
A prostate cancer vaccine containing six messenger RNAs (mRNAs) encoding for antigens upregulated in prostate cancer, including mRNAs for prostate… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2013-2015
0120132015

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
BACKGROUND CV9103 is a prostate-cancer vaccine containing self-adjuvanted mRNA (RNActive®) encoding the antigens PSA, PSCA, PSMA… (More)
Is this relevant?
Review
2014
Review
2014
Among currently available vaccine strategies for cancer, nucleotide-based vaccination is an appealing treatment modality… (More)
Is this relevant?
2014
2014
A randomized, double-blind, placebo-controlled, Phase I/II trial of RNActive®-vaccine cv9104 in patients with metastatic castrate… (More)
Is this relevant?
2013